Attached files

file filename
EX-32.1 - EX-32.1 - CYTOKINETICS INCcytk-ex321_7.htm
EX-31.3 - EX-31.3 - CYTOKINETICS INCcytk-ex313_9.htm
EX-31.2 - EX-31.2 - CYTOKINETICS INCcytk-ex312_6.htm
EX-31.1 - EX-31.1 - CYTOKINETICS INCcytk-ex311_10.htm
EX-10.61 - EX-10.61 - CYTOKINETICS INCcytk-ex1061_196.htm
EX-10.60 - EX-10.60 - CYTOKINETICS INCcytk-ex1060_197.htm
EX-10.59 - EX-10.59 - CYTOKINETICS INCcytk-ex1059_198.htm
10-K - 10-K - CYTOKINETICS INCcytk-10k_20201231.htm

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following Registration Statements:

 

 

1)

Registration Statements (Form S-3 Nos. 333-215147, 333-221350, 333-231348 and 333-234537) of Cytokinetics, Incorporated, and

 

2)

Registration Statements (Form S-8 Nos. 333-115146, 333-125973, 333-133323, 333-136524, 333-140963, 333-149713, 333-152850, 333-161116, 333-168520, 333-176089, 333-183091, 333-190458, 333-206101, 333-221348, 333-236889 and 333-238786) pertaining to the Amended and Restated 2004 Equity Incentive Plan of Cytokinetics, Incorporated;

 

of our reports dated February 26, 2021, with respect to the consolidated financial statements of Cytokinetics, Incorporated and the effectiveness of internal control over financial reporting of Cytokinetics, Incorporated included in this Annual Report (Form 10-K) of Cytokinetics, Incorporated for the year ended December 31, 2020.

 

/s/ Ernst & Young LLP

 

Redwood City, California

February 26, 2021